침습성 아스페르길루스증 진단을 위한 갈락토만난 항원 검사의 유용성 평가
Diagnostic Usefulness of Galactomannan Assay for Invasive Aspergillosis
1
조회
0
다운로드
4
인용
0
참고문헌
키워드
초록
Background : Invasive aspergillosis (IA) is an important cause of morbidity and mortality among immunocompromised patients. However, IA is difficult to diagnose, especially in the aforementioned patient group. Recently, galactomannan assay (GMA) using enzyme immunoassay has been introduced in Korea. We evaluated its diagnostic usefulness in the diagnosis of IA and we analyzed the results according to the underlying diseases. Materials and Methods : All patients who underwent GMA during the period from October 2007 to June 2008 were evaluated retrospectively. According to the criteria of European Organization for Research and Treatment of Cancer/Mycoses Study Group, IA was classified into four clinical categories: ‘proven’, ‘probable’, ‘possible’, and ‘non’ IA. Patients with ‘proven’ and ‘probable’ IA were used as the reference standards for IA. GMA was performed using Platelia Aspergillus EIA (Bio-Rad, Hercules, CA, USA). Optical density index ≥0.5 was considered positive. Results : Of the 144 patients who underwent GMA, two patients were classificed as ‘proven’ IA and sixteen patients were ‘probable’ IA. Overall sensitivity, specificity, positive predictive value, and negative predictive value of the assay were 50% (95% confidence interval [CI95], 26-74%), 88% (CI95, 81-93%), 38% (CI95, 19-59%), and 93% (CI95, 86-97%), respectively. Among the 99 patients with underlying hematologic diseases, GMA showed 67% (CI95, 35-90%) sensitivity and 89% (CI95, 80- 94%) specificity, whereas in 45 patients with underlying diseases other than hematologic diseases, sensitivity and specificity of the assay were 17% (CI95, 0-64%) and 87% (CI95, 73-96%), respectively. Conclusions : GMA showed high specificity, irrespective of the patient population. However, sensitivity of GMA was low and the assay was less sensitive in patients with underlying diseases other than hematologic diseases than in patients with hematologic diseases.
Abstract
Background : Invasive aspergillosis (IA) is an important cause of morbidity and mortality among immunocompromised patients. However, IA is difficult to diagnose, especially in the aforementioned patient group. Recently, galactomannan assay (GMA) using enzyme immunoassay has been introduced in Korea. We evaluated its diagnostic usefulness in the diagnosis of IA and we analyzed the results according to the underlying diseases. Materials and Methods : All patients who underwent GMA during the period from October 2007 to June 2008 were evaluated retrospectively. According to the criteria of European Organization for Research and Treatment of Cancer/Mycoses Study Group, IA was classified into four clinical categories: ‘proven’, ‘probable’, ‘possible’, and ‘non’ IA. Patients with ‘proven’ and ‘probable’ IA were used as the reference standards for IA. GMA was performed using Platelia Aspergillus EIA (Bio-Rad, Hercules, CA, USA). Optical density index ≥0.5 was considered positive. Results : Of the 144 patients who underwent GMA, two patients were classificed as ‘proven’ IA and sixteen patients were ‘probable’ IA. Overall sensitivity, specificity, positive predictive value, and negative predictive value of the assay were 50% (95% confidence interval [CI95], 26-74%), 88% (CI95, 81-93%), 38% (CI95, 19-59%), and 93% (CI95, 86-97%), respectively. Among the 99 patients with underlying hematologic diseases, GMA showed 67% (CI95, 35-90%) sensitivity and 89% (CI95, 80- 94%) specificity, whereas in 45 patients with underlying diseases other than hematologic diseases, sensitivity and specificity of the assay were 17% (CI95, 0-64%) and 87% (CI95, 73-96%), respectively. Conclusions : GMA showed high specificity, irrespective of the patient population. However, sensitivity of GMA was low and the assay was less sensitive in patients with underlying diseases other than hematologic diseases than in patients with hematologic diseases.
참고문헌 (27)
- Marr KA, "Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients", Clin Infect Dis, 34, pp.909~917 (2002)
- Herbrecht R, "Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis", N Engl J Med, 347, pp.408~415 (2002)
- Bruno C, "Comparison of CT features of Aspergillus and bacterial pneumonia in severely neutropenic patients", J Thorac Imaging, 22, pp.160~165 (2007)
- Reichenberger F, "Diagnostic yield of bronchoscopy in histologically proven invasive pulmonary aspergillosis", Bone Marrow Transplant, 24, pp.1195~1199 (1999)
- Mennink-Kersten MA, "Detection of circulating galactomannan for the diagnosis and management of invasive aspergillosis", Lancet Infect Dis, 4, pp.349~357 (2004)
- Stynen D, "A new sensitive sandwich enzyme-linked immunosorbent assay to detect galactofuran in patients with invasive aspergillosis", J Clin Microbiol, 33, pp.497~500 (1995)
- Verweij PE, "Sandwich enzyme-linked immunosorbent assay compared with Pastorex latex agglutination test for diagnosing invasive aspergillosis in immunocompromised patients", J Clin Microbiol, 33, pp.1912~1914 (1995)
- Lombardi G, "Multicenter evaluation of an enzyme immunoassay (Platelia Aspergillus) for the detection of Aspergillus antigen in serum", Mycopathologia, 155, pp.129~133 (2002)
- Yoo JH, "Application of nucleic acid sequence-based amplification for diagnosis of and monitoring the clinical course of invasive aspergillosis in patients with hematologic diseases", Clin Infect Dis, 40, pp.392~398 (2005)
- 성흥섭, "침습성 아스페르길루스증 진단을 위한 Platelia Aspergillus 항원 검사법의 평가", Annals of Clinical Microbiology, 8(2), pp.113~120 (2005), 대한임상미생물학회
- Ascioglu S, "Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus", Clin Infect Dis, 34, pp.7~14 (2002)
- Yoo JH, "Outlines and principles of treatment of fungal infection in Infectious Diseases" (2007), Koonja Co.
- Wheat LJ, "Diagnosis of invasive aspergillosis by galactomannan antigenemia detection using an enzyme immunoassay", Eur J Clin Microbiol Infect Dis, 27, pp.245~251 (2008)
- Newcombe RG, "Two-sided confidence intervals for the single proportion: comparison of seven methods", Stat Med, 17, pp.857~872 (1998)
- Fortun J, "Aspergillus antigenemia sandwich-enzyme immunoassay test as a serodiagnostic method for invasive aspergillosis in liver transplant recipients", Transplantation, 71, pp.145~149 (2001)
- Husain S, "Prospective assessment of Platelia Aspergillus galactomannan antigen for the diagnosis of invasive aspergillosis in lung transplant recipients", Am J Transplant, 4, pp.796~802 (2004)
- Pfeiffer CD, "Diagnosis of invasive aspergillosis using a galactomannan assay: a meta- analysis", Clin Infect Dis, 42, pp.1417~1427 (2006)
- Pasqualotto AC, "Post-operative aspergillosis", Clin Microbiol Infect, 12, pp.1060~1076 (2006)
- Aquino VR, "on the contribution of galactomannan for the diagnosis of invasive aspergillosis", Mycopathologia, 163, pp.191~202 (2007)
- Balloy V, "Differences in patterns of infection and inflammation for corticosteroid treatment and chemotherapy in experimental invasive pulmonary aspergillosis", Infect Immun, 73, pp.494~503 (2005)
- Marr KA, "Detection of galactomannan antigenemia by enzyme immunoassay for the diagnosis of invasive aspergillosis: variables that affect performance", J Infect Dis, 190, pp.641~649 (2004)
- Maertens J, "Prospective clinical evaluation of lower cut-offs for galactomannan detection in adult neutropenic cancer patients and haematological stem cell transplant recipients", Br J Haematol, 126, pp.852~860 (2004)
- Verweij PE, "The Dutch Interuniversity Working Party for Invasive Mycoses", J Clin Microbiol, 36, pp.1612~1616 (1998)
- Wheat LJ, "Rapid diagnosis of invasive aspergillosis by antigen detection", Transpl Infect Dis, 5, pp.158~166 (2003)
- Maertens J, "Use of circulating galactomannan screening for early diagnosis of invasive aspergillosis in allogeneic stem cell transplant recipients", J Infect Dis, 186, pp.1297~1306 (2002)
- Whiting P, "Sources of variation and bias in studies of diagnostic accuracy: a systematic review", Ann Intern Med, 140, pp.189~202 (2004)
- De Pauw B, "Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer", Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC, Clin Infect Dis, pp.2008, 46[DOI]